Growth & profitability
- Revenue has grown 29.5% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
NRIX Financials Nurix Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | -$264M | 0.0% | -340.2% | -$263M | — | $247M |
| 2024 | $55M | -$194M | 0.0% | -390.5% | -$182M | — | $110M |
| 2023 | $77M | -$144M | 0.0% | -201.4% | -$90M | — | $55M |
| 2022 | $39M | -$180M | 0.0% | -476.0% | -$172M | — | $64M |
| 2021 | — | -$117M | — | — | -$90M | — | $81M |
| 2020 | — | -$43M | — | — | -$5M | — | $119M |
| 2019 | — | -$22M | — | — | -$1M | — | $35M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Feb '26 | $6M | -$87M | 0.0% | -1479.4% | -$73M | — | $71M |
| Nov '25 | $14M | -$78M | 0.0% | -612.0% | -$73M | — | $247M |
| Aug '25 | $8M | -$86M | 0.0% | -1157.7% | -$60M | — | $78M |
| May '25 | $44M | -$43M | 0.0% | -109.7% | -$66M | — | $84M |
| Feb '25 | $18M | -$56M | 0.0% | -340.7% | -$65M | — | $76M |
| Nov '24 | $13M | -$59M | 0.0% | -486.7% | -$51M | — | $110M |
| Aug '24 | $13M | -$49M | 0.0% | -433.8% | -$45M | — | $99M |
| May '24 | $12M | -$45M | 0.0% | -401.4% | -$42M | — | $117M |
| Feb '24 | $17M | -$42M | 0.0% | -272.6% | -$45M | — | $50M |
| Nov '23 | $15M | -$42M | 0.0% | -299.1% | $24M | — | $55M |
| Aug '23 | $18M | -$37M | 0.0% | -216.7% | -$44M | — | $42M |
| May '23 | $31M | -$24M | 0.0% | -87.3% | -$20M | — | $59M |
| Feb '23 | — | -$41M | — | — | -$51M | — | $34M |
| Nov '22 | — | -$47M | — | — | -$41M | — | $64M |
| Aug '22 | — | -$46M | — | — | -$50M | — | $48M |
| May '22 | — | -$45M | — | — | -$36M | — | $42M |
| Feb '22 | — | -$43M | — | — | -$46M | — | $79M |
| Nov '21 | — | -$38M | — | — | -$32M | — | $81M |
| Aug '21 | — | -$29M | — | — | -$32M | — | $147M |
| May '21 | — | -$26M | — | — | -$34M | — | $188M |
Valuation over time
How the market has priced NRIX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 23.7× (Mar '23) to 27.6× (Jun '26).
P/S
Frequently asked questions
Is NRIX growing its revenue and profit?
Over the past 5 years, Nurix Therapeutics, Inc.'s revenue has grown 29.5% per year. These are computed facts, not advice.
How much debt does NRIX have?
As of FY2025, Nurix Therapeutics, Inc. reported — of total debt against $247M of cash.
What is NRIX's profit margin?
In FY2025, gross margin was —, operating margin -340.2%, and net margin -314.9%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.